Valproic acid silencing of ascl1b/Ascl1 results in the failure of serotonergic differentiation in a zebrafish model of fetal valproate syndrome

@inproceedings{Jacob2014ValproicAS,
  title={Valproic acid silencing of ascl1b/Ascl1 results in the failure of serotonergic differentiation in a zebrafish model of fetal valproate syndrome},
  author={J. Jacob and Vanessa Ribes and Steven Moore and Sean C. Constable and Noriaki Sasai and Sebastian S. Gerety and Darren J. Martin and Chris P. Sergeant and David G Wilkinson and James Briscoe},
  booktitle={Disease models & mechanisms},
  year={2014}
}
Fetal valproate syndrome (FVS) is caused by in utero exposure to the drug sodium valproate. Valproate is used worldwide for the treatment of epilepsy, as a mood stabiliser and for its pain-relieving properties. In addition to birth defects, FVS is associated with an increased risk of autism spectrum disorder (ASD), which is characterised by abnormal behaviours. Valproate perturbs multiple biochemical pathways and alters gene expression through its inhibition of histone deacetylases. Which, if… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 12 times over the past 90 days. VIEW TWEETS
9 Citations
103 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 103 references

5 - HT 1 Areceptor agonist modified amygdala activity and amygdalaassociated social behavior in a valproateinduced rat autism model

  • H. C. Lin, Y. H. Chan, P. W. Gean, Y. K. Yang, P. S. Chen
  • Int . J . Neuropsychopharmacol .
  • 2013

Similar Papers

Loading similar papers…